journal
MENU ▼
Read by QxMD icon Read
search

Blood Cancer Journal

journal
https://www.readbyqxmd.com/read/27935581/comprehensive-study-on-erg-gene-expression-in-normal-karyotype-acute-myeloid-leukemia-erg-expression-is-of-limited-prognostic-value-whereas-the-accumulation-of-adverse-prognostic-markers-stepwise-worsens-the-prognosis
#1
https://www.readbyqxmd.com/read/27935580/second-malignancies-in-the-context-of-lenalidomide-treatment-an-analysis-of-2732-myeloma-patients-enrolled-to-the-myeloma-xi-trial
#2
J R Jones, D A Cairns, W M Gregory, C Collett, C Pawlyn, R Sigsworth, A Striha, R Henderson, M F Kaiser, M Jenner, G Cook, N H Russell, C Williams, G Pratt, B Kishore, J Lindsay, M T Drayson, F E Davies, K D Boyd, R G Owen, G H Jackson, G J Morgan
We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary malignancy (SPM) incidence and pathology. After review, 104 SPMs were confirmed in 96 of 2732 trial patients. The cumulative incidence of SPM was 0.7% (95% confidence interval (CI) 0.4-1.0%), 2.3% (95% CI 1.6-2.7%) and 3.8% (95% CI 2.9-4.6%) at 1, 2 and 3 years, respectively. Patients receiving maintenance lenalidomide had a significantly higher SPM incidence overall (P=0...
December 9, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27935579/mir-139-5p-is-a-potent-tumor-suppressor-in-adult-acute-myeloid-leukemia
#3
K Krowiorz, J Ruschmann, C Lai, M Ngom, T Maetzig, V Martins, A Scheffold, E Schneider, N Pochert, C Miller, L Palmqvist, A Staffas, M Mulaw, S R Bohl, C Buske, M Heuser, J Kraus, K O'Neill, C L Hansen, O I Petriv, H Kestler, H Döhner, L Bullinger, K Döhner, R K Humphries, A Rouhi, F Kuchenbauer
No abstract text is available yet for this article.
December 9, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27935578/comment-on-blinatumomab-vs-historical-standard-therapy-of-adult-relapsed-refractory-acute-lymphoblastic-leukemia
#4
W H Tong
No abstract text is available yet for this article.
December 9, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27935577/bone-marrow-fibrosis-grade-is-an-independent-risk-factor-for-overall-survival-in-patients-with-primary-myelofibrosis
#5
B Li, P Zhang, G Feng, Z Xu, T Qin, Y Zhang, Z Sha, D Dong, H Zhang, L Fang, L Pan, N Hu, S Qu, W Cai, G Huang, Z Xiao
No abstract text is available yet for this article.
December 9, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27935576/acute-lymphoblastic-leukemia-relapsing-after-first-line-pediatric-inspired-therapy-a-retrospective-graall-study
#6
A Desjonquères, P Chevallier, X Thomas, F Huguet, T Leguay, M Bernard, J-O Bay, E Tavernier, A Charbonnier, F Isnard, M Hunault, P Turlure, M Renaud, J-N Bastié, C Himberlin, S Lepretre, B Lioure, V Lhéritier, V Asnafi, K Beldjord, M Lafage-Pochitaloff, M C Béné, N Ifrah, H Dombret
The outcome of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) relapsing after pediatric-inspired front-line therapy is ill known. Here 229 relapsing Ph- ALL younger adults (18-63 years) treated within the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-2003/-2005 trials were considered. Salvage regimens consisted of potentially curative therapies in 194 cases, low-intensity therapies in 21, allogeneic stem cell transplant (allo-SCT) in 6 and best supportive care in 8...
December 9, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27911437/the-role-of-the-proteasome-in-aml
#7
REVIEW
C M Csizmar, D-H Kim, Z Sachs
Acute myeloid leukemia (AML) is deadly hematologic malignancy. Despite a well-characterized genetic and molecular landscape, targeted therapies for AML have failed to significantly improve clinical outcomes. Over the past decade, proteasome inhibition has been demonstrated to be an effective therapeutic strategy in several hematologic malignancies. Proteasome inhibitors, such as bortezomib and carfilzomib, have become mainstays of treatment for multiple myeloma and mantle cell lymphoma. In light of this success, there has been a surge of literature exploring both the role of the proteasome and the effects of proteasome inhibition in AML...
December 2, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27911436/uncovering-molecular-abnormalities-leading-to-the-warburg-effect-in-primary-refractory-diffuse-large-b-cell-lymphoma
#8
M Soleja, M Mims, G Rivero
No abstract text is available yet for this article.
December 2, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27858932/plasma-immunoprofiling-of-patients-with-high-risk-diffuse-large-b-cell-lymphoma-a-nordic-lymphoma-group-study
#9
F Pauly, K Fjordén, S Leppä, H Holte, M Björkholm, Ø Fluge, L Møller Pedersen, M Eriksson, A Isinger-Ekstrand, C A K Borrebaeck, M Jerkeman, C Wingren
No abstract text is available yet for this article.
November 18, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834943/idelalisib-improves-cd37-antibody-bi-836826-cytotoxicity-against-chemo-resistant-relapse-initiating-cll-cells-a-rationale-for-combination-treatment
#10
S Betrian, L Ysebaert, K H Heider, J P Delord, J J Fournié, A Quillet-Mary
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834942/measurement-of-%C3%AE-isomerized-c-terminal-telopeptide-of-type-i-collagen-in-patients-with-poems-syndrome-diagnostic-prognostic-and-follow-up-utilities
#11
X Huang, C Zhang, C Wang, Q Cai, X Cao, H Cai, L Zhang, J Feng, D Zhou, J Li
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834941/in-vivo-magnetic-resonance-imaging-of-a-mouse-model-of-myelofibrosis
#12
S Matsuura, S Patterson, H Lucero, O Leiva, A K Grant, V L M Herrera, K Ravid
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834940/high-prevalence-of-viral-hepatitis-in-a-series-of-splenic-marginal-zone-lymphomas-from-romania
#13
B Fetica, B Pop, M L Blaga, A Fulop, D Dima, M T Zdrenghea, C I Vlad, A S Bojan, P Achimas-Cadariu, C I Lisencu, A Irimie, D D Weisenburger
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834939/kinase-associated-gene-mutation-pattern-and-clinical-relevance-in-205-patients-with-core-binding-factor-leukemias
#14
Y-S Chen, P-P Wang, Y Hu, Y-M Zhu, B Chen, J-Y Huang, J-M Li, X-Q Weng, Y Yu, Y Shen
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834938/overexpression-of-rankl-by-invariant-nkt-cells-enriched-in-the-bone-marrow-of-patients-with-multiple-myeloma
#15
E Spanoudakis, M Papoutselis, E Terpos, M A Dimopoulos, C Tsatalas, D Margaritis, A Rahemtulla, I Kotsianidis, A Karadimitris
No abstract text is available yet for this article.
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27834937/improved-survival-for-patients-diagnosed-with-chronic-lymphocytic-leukemia-in-the-era-of-chemo-immunotherapy-a-danish-population-based-study-of-10455-patients
#16
C da Cunha-Bang, J Simonsen, K Rostgaard, C Geisler, H Hjalgrim, C U Niemann
The treatment of chronic lymphocytic leukemia (CLL) is in rapid transition, and during recent decades both combination chemotherapy and immunotherapy have been introduced. To evaluate the effects of this development, we identified all CLL patients registered in the nation-wide Danish Cancer Register between 1978 and 2013. We identified 10 455 CLL patients and 508 995 CLL-free control persons from the general population. Compared with the latter, the relative mortality rate between CLL patients and their controls decreased from 3...
November 11, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27813537/conflict-of-interest-in-academic-oncology-moving-beyond-the-blame-game-and-forging-a-path-forward
#17
EDITORIAL
V Prasad, S V Rajkumar
No abstract text is available yet for this article.
November 4, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27813536/clinical-significance-of-trisomy-8-that-emerges-during-therapy-in-chronic-myeloid-leukemia
#18
W Wang, Z Chen, Z Hu, C C Yin, S Li, S Bai, C E Bueso-Ramos, L J Medeiros, S Hu
No abstract text is available yet for this article.
November 4, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27813535/coinhibition-of-the-deubiquitinating-enzymes-usp14-and-uchl5-with-vlx1570-is-lethal-to-ibrutinib-or-bortezomib-resistant-waldenstrom-macroglobulinemia-tumor-cells
#19
A Paulus, S Akhtar, T R Caulfield, K Samuel, H Yousaf, Y Bashir, S M Paulus, D Tran, R Hudec, D Cogen, J Jiang, B Edenfield, A Novak, S M Ansell, T Witzig, P Martin, M Coleman, V Roy, S Ailawadhi, K Chitta, S Linder, A Chanan-Khan
The survival of Waldenstrom macroglobulinemia (WM) tumor cells hinges on aberrant B-cell receptor (BCR) and MYD88 signaling. WM cells upregulate the proteasome function to sustain the BCR-driven growth while maintaining homeostasis. Clinically, two treatment strategies are used to disrupt these complementary yet mutually exclusive WM survival pathways via ibrutinib (targets BTK/MYD88 node) and bortezomib (targets 20 S proteasome). Despite the success of both agents, WM patients eventually become refractory to treatment, highlighting the adaptive plasticity of WM cells and underscoring the need for development of new therapeutics...
November 4, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27813534/splanchnic-vein-thrombosis-in-myeloproliferative-neoplasms-risk-factors-for-recurrences-in-a-cohort-of-181-patients
#20
V De Stefano, A M Vannucchi, M Ruggeri, F Cervantes, A Alvarez-Larrán, A Iurlo, M L Randi, L Pieri, E Rossi, P Guglielmelli, S Betti, E Elli, M C Finazzi, G Finazzi, E Zetterberg, N Vianelli, G Gaidano, I Nichele, D Cattaneo, M Palova, M H Ellis, E Cacciola, A Tieghi, J C Hernandez-Boluda, E Pungolino, G Specchia, D Rapezzi, A Forcina, C Musolino, A Carobbio, M Griesshammer, T Barbui
We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd-Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4...
November 4, 2016: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"